{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:39:31Z","timestamp":1789213171075,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T00:00:00Z","timestamp":1351209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s10753-012-9559-x","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T11:45:20Z","timestamp":1351165520000},"page":"405-412","source":"Crossref","is-referenced-by-count":13,"title":["Urotensin Inhibition with Palosuran Could Be a Promising Alternative in Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"36","author":[{"given":"Ahmet Mesut","family":"Onat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Halil","family":"Turkbeyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncer","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davut Sinan","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Osman","family":"Ceribasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Orkmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ediz","family":"Tutar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyithan","family":"Taysi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Sayarlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunyamin","family":"Kisacik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,26]]},"reference":[{"key":"9559_CR1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1161\/CIRCULATIONAHA.104.503540","volume":"114","author":"VV McLaughlin","year":"2006","unstructured":"McLaughlin, V.V., and M.D. McGoon. 2006. Pulmonary arterial hypertension. Circulation 114: 1417\u20131431.","journal-title":"Circulation"},{"key":"9559_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/107424840200700i102","volume":"7","author":"NHS Kim","year":"2002","unstructured":"Kim, N.H.S., and L.J. Rubin. 2002. Endothelin in health and disease: Endothelin receptor antagonists in the management of pulmonary artery hypertension. Journal of Cardiovascular Pharmacology Therapeutics 7: 9\u201319.","journal-title":"Journal of Cardiovascular Pharmacology Therapeutics"},{"key":"9559_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjp.0703601","volume":"131","author":"JJ Maguire","year":"2000","unstructured":"Maguire, J.J., R.E. Kuc, and A.P. Davenport. 2000. Orphan-receptor ligand human urotensin II: Receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. British Journal of Pharmacology 131: 441\u2013446.","journal-title":"British Journal of Pharmacology"},{"key":"9559_CR4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","volume":"401","author":"RS Ames","year":"1999","unstructured":"Ames, R.S., H.M. Sarau, J.K. Chambers, R.N. Willette, N.V. Aiyar, A.M. Romanic, et al. 1999. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282\u2013286.","journal-title":"Nature"},{"key":"9559_CR5","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/01.CIR.103.10.1378","volume":"103","author":"C Hillier","year":"2001","unstructured":"Hillier, C., C. Berry, M.C. Petrie, P.J. O'Dwyer, C. Hamilton, A. Brown, et al. 2001. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103: 1378\u20131381.","journal-title":"Circulation"},{"key":"9559_CR6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/01.RES.0000184670.58688.9F","volume":"97","author":"G Giebing","year":"2005","unstructured":"Giebing, G., M. T\u00f6lle, J. J\u00fcrgensen, J. Eichhorst, J. Furkert, M. Beyermann, et al. 2005. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circulation Research 97: 707\u2013715.","journal-title":"Circulation Research"},{"key":"9559_CR7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1160\/TH07-04-0294","volume":"98","author":"T Djordjevic","year":"2007","unstructured":"Djordjevic, T. 2007. Go\u0308rlach A. Urotensin-II in the lung: A matter for vascular remodelling and pulmonary hypertension? Thrombosis and Haemostasis 98: 952\u2013962.","journal-title":"Thrombosis and Haemostasis"},{"key":"9559_CR8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.bjp.0704924","volume":"137","author":"JJ Maguire","year":"2002","unstructured":"Maguire, J.J., and A.P. Davenport. 2002. Is urotensin-II the new endothelin? British Journal of Pharmacology 137: 579\u2013588.","journal-title":"British Journal of Pharmacology"},{"key":"9559_CR9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10067-011-1688-3","volume":"30","author":"Y Pehlivan","year":"2011","unstructured":"Pehlivan, Y., A.M. Onat, G. Comez, and T. Babacan. 2011. Urotensin-II in systemic sclerosis: A new peptide in pathogenesis. Clinical Rheumatology 30: 837\u2013842.","journal-title":"Clinical Rheumatology"},{"key":"9559_CR10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3899\/jrheum.110509","volume":"39","author":"Y Pehlivan","year":"2012","unstructured":"Pehlivan, Y., B. Gogebakan, S. Oztuzcu, M. Ozgen, G.Y. Cetin, R. Bayraktar, et al. 2012. Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II Gene and systemic sclerosis. The Journal of Rheumatology 39: 106\u2013111.","journal-title":"The Journal of Rheumatology"},{"issue":"suppl3","key":"9559_CR11","first-page":"410","volume":"69","author":"AM Onat","year":"2010","unstructured":"Onat, A.M., I. Turkbeyler, Y. Pehlivan, T. Demir, D.S. Kaplan, S. Taysi, et al. 2010. Urotensin II antogonism with palosuran: A new treatment in pulmonary arterial hypertension. Annals of the Rheumatic Diseases 69(suppl3): 410.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"9559_CR12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pupt.2011.03.003","volume":"24","author":"Y Mei","year":"2011","unstructured":"Mei, Y., H. Jin, W. Tian, H. Wang, H. Wang, Y. Zhao, et al. 2011. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats. Pulmonary Pharmacology & Therapeutics 24: 386\u2013393.","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"9559_CR13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1124\/jpet.104.068320","volume":"311","author":"M Clozel","year":"2004","unstructured":"Clozel, M., C. Binkert, M. Birker-Robaczewska, C. Boukhadra, S.S. Ding, W. Fischli, et al. 2004. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl- quinolin-4-yl)-urea sulfate salt): First demonstration of a pathophysiological role of the urotensin system. The Journal of Pharmacology and Experimental Therapeutics 311: 204\u2013212.","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"9559_CR14","first-page":"85","volume":"50","author":"B Alexandru","year":"2001","unstructured":"Alexandru, B., and M.A. Bogdan. 2001. Monocrotaline induces pulmonary hypertension in animal models. Pneumologia 50: 85\u201389.","journal-title":"Pneumologia"},{"key":"9559_CR15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1124\/jpet.105.094821","volume":"316","author":"M Clozel","year":"2006","unstructured":"Clozel, M., P. Hess, C. Qiu, S.S. Ding, and M. Rey. 2006. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. The Journal of Pharmacology and Experimental Therapeutics 316: 1115\u20131121.","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"9559_CR16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1152\/jappl.1981.51.4.1047","volume":"51","author":"RB Stinger","year":"1981","unstructured":"Stinger, R.B., V.J. Iacopino, I. Alter, T.M. Fitzpatrick, J.C. Rose, and P.A. Kot. 1981. Catheterization of the pulmonary artery in the closed-chest rat. Journal of Applied Physiology 51: 1047\u20131050.","journal-title":"Journal of Applied Physiology"},{"key":"9559_CR17","first-page":"541","volume":"26","author":"XD Zhu","year":"2010","unstructured":"Zhu, X.D., D.M. Shi, Z.C. Jing, Z.C. Jing, L. Li, D. Ma, et al. 2010. The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats. International Journal of Molecular Medicine 26: 541\u2013547.","journal-title":"International Journal of Molecular Medicine"},{"key":"9559_CR18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1152\/ajpheart.00970.2005","volume":"290","author":"J Varagic","year":"2006","unstructured":"Varagic, J., E.D. Frohlich, J. D\u00edez, D. Susic, J. Ahn, A. Gonz\u00e1lez, et al. 2006. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. American Journal of Physiology. Heart and Circulatory Physiology 290: 1503\u20131509.","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"9559_CR19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1164\/rccm.2310015","volume":"169","author":"IM Robbins","year":"2004","unstructured":"Robbins, I.M. 2004. Advancing therapy for pulmonary arterial hypertension: Can animal models help? American Journal of Respiratory and Critical Care Medicine 169: 5\u20136.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"9559_CR20","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"VV McLaughlin","year":"2009","unstructured":"McLaughlin, V.V., S.L. Archer, D.B. Badesch, R.J. Barst, H.W. Farber, J.R. Lindner, et al. 2009. American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association: ACCF\/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the AmericanCollege of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. Journal of the American College of Cardiology 53: 1573\u20131619.","journal-title":"Journal of the American College of Cardiology"},{"key":"9559_CR21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5830\/CVJA-2010-088","volume":"21","author":"MR Essop","year":"2010","unstructured":"Essop, M.R. 2010. Contemporary insights into the pathogenesis, diagnosis and therapy of pulmonary arterial hypertension. Cardiovascular Journal of Africa 21: 334\u2013337.","journal-title":"Cardiovascular Journal of Africa"},{"key":"9559_CR22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","volume":"114","author":"DJ Stewart","year":"1991","unstructured":"Stewart, D.J., R.D. Levy, P. Cernacek, and D. Langleben. 1991. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Annals of Internal Medicine 114: 464\u2013469.","journal-title":"Annals of Internal Medicine"},{"key":"9559_CR23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","volume":"120","author":"C Rubens","year":"2001","unstructured":"Rubens, C., R. Ewert, M. Halank, R. Wensel, H.D. Orzechowski, H.P. Schultheiss, et al. 2001. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120: 1562\u20131569.","journal-title":"Chest"},{"key":"9559_CR24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.ATV.0000154279.98244.eb","volume":"25","author":"T Djordjevic","year":"2005","unstructured":"Djordjevic, T., R.S. BelAiba, S. Bonello, J. Pfeilschifter, J. Hess, and A. G\u00f6rlach. 2005. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 519\u2013525.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"9559_CR25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00380-003-0739-3","volume":"19","author":"J Qi","year":"2004","unstructured":"Qi, J., J. Du, X. Tang, J. Li, B. Wei, and C. Tang. 2004. The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart and Vessels 19: 81\u201388.","journal-title":"Heart and Vessels"},{"key":"9559_CR26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjp.0703314","volume":"130","author":"MR MacLean","year":"2000","unstructured":"MacLean, M.R., D. Alexander, A. Stirrat, M. Gallagher, S.A. Douglas, E.H. Ohlstein, et al. 2000. Contractile responses to human urotensin-II in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat. British Journal of Pharmacology 130: 201\u2013204.","journal-title":"British Journal of Pharmacology"},{"key":"9559_CR27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.regpep.2009.04.006","volume":"157","author":"G Albertin","year":"2009","unstructured":"Albertin, G., D. Guidolin, E. Sorato, R. Spinazzi, A. Mascarin, B. Oselladore, et al. 2009. Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations. Regulatory Peptides 157: 64\u201371.","journal-title":"Regulatory Peptides"},{"key":"9559_CR28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/01.RES.0000201960.04223.3c","volume":"98","author":"G Loirand","year":"2006","unstructured":"Loirand, G., P. Guerin, and P. Pacaud. 2006. Rho kinases in cardiovascular physiology and pathophysiology. Circulation Research 98: 322\u2013334.","journal-title":"Circulation Research"},{"key":"9559_CR29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.RES.0000111804.34509.94","volume":"94","author":"K Abe","year":"2004","unstructured":"Abe, K., H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, et al. 2004. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circulation Research 94: 385\u2013393.","journal-title":"Circulation Research"},{"key":"9559_CR30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/bjp.2008.239","volume":"155","author":"M Oka","year":"2008","unstructured":"Oka, M., K.A. Fagan, P.L. Jones, and I.F. McMurtry. 2008. Therapeutic potential of RhoA\/Rho kinase inhibitors in pulmonary hypertension. British Journal of Pharmacology 155: 444\u2013454.","journal-title":"British Journal of Pharmacology"},{"key":"9559_CR31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/hrt.2003.029470","volume":"91","author":"Y Fukumoto","year":"2005","unstructured":"Fukumoto, Y., T. Matoba, A. Ito, H. Tanaka, T. Kishi, S. Hayashidani, et al. 2005. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91: 391\u2013392.","journal-title":"Heart"},{"key":"9559_CR32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00380-009-1176-8","volume":"25","author":"H Fujita","year":"2010","unstructured":"Fujita, H., Y. Fukumoto, K. Saji, K. Sugimura, J. Demachi, J. Nawata, et al. 2010. Acute vasodilator effects of inhaled fasudil, a specific Rhokinase inhibitor, in patients with pulmonary arterial hypertension. Heart and Vessels 25: 144\u2013149.","journal-title":"Heart and Vessels"},{"key":"9559_CR33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1253\/circj.70.174","volume":"70","author":"K Ishikura","year":"2006","unstructured":"Ishikura, K., N. Yamada, M. Ito, S. Ota, M. Nakamura, N. Isaka, et al. 2006. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circulation Journal 70: 174\u2013178.","journal-title":"Circulation Journal"},{"key":"9559_CR34","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/hh1101.092034","volume":"88","author":"V Sauzeau","year":"2001","unstructured":"Sauzeau, V., E.L. Mellionnec, J. Bertoglio, E. Scalbert, P. Pacaud, and G. Loirand. 2001. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by Rho A and Rho-kinase. Circulation Research 88: 1102\u20131104.","journal-title":"Circulation Research"},{"key":"9559_CR35","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/00004872-200112000-00012","volume":"19","author":"T Watanabe","year":"2001","unstructured":"Watanabe, T., R. Pakala, T. Katagiri, and C.R. Benedict. 2001. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. Journal of Hypertension 19: 2191\u20132196.","journal-title":"Journal of Hypertension"},{"key":"9559_CR36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0014-2999(02)01341-9","volume":"438","author":"WJ Rossowski","year":"2002","unstructured":"Rossowski, W.J., B.L. Cheng, J.E. Taylor, R. Datta, and D.H. Coy. 2002. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: Inhibition by somatostatin receptor antagonists. European Journal of Pharmacology 438: 159\u2013170.","journal-title":"European Journal of Pharmacology"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-012-9559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10753-012-9559-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-012-9559-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:12:44Z","timestamp":1562285564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10753-012-9559-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,26]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["9559"],"URL":"https:\/\/doi.org\/10.1007\/s10753-012-9559-x","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,26]]}}}